Sabina Chiaretti
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 140 publications
Favorable outcomes after early allogeneic stem cell transplantation in adult early T-cell precursor acute lymphoblastic leukemia treated with the pediatric-inspired GIMEMA LAL1913 program. A Campus ALL study.
Journal: Bone marrow transplantation
Published: May 27, 2026
Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants.
Journal: European journal of haematology
Published: April 27, 2026
Comparative Analysis Between the EuroClonality-NGS Approach and the LymphoTrack® Dx Assay for IG/TR Marker Screening in Lymphoid Leukemias: A Campus ALL Study.
Journal: International journal of molecular sciences
Published: April 24, 2026
Allogeneic stem cell transplantation in adult Ph-like acute lymphoblastic leukemia. Results from two consecutive GIMEMA protocols.
Journal: Bone marrow transplantation
Published: March 18, 2026
Real-world effectiveness and safety of blinatumomab in adults with B-cell precursor acute lymphoblastic leukaemia across 13 European countries.
Journal: Blood cancer journal
Published: December 19, 2025
Optimal management of elderly/old Ph+ acute lymphoblastic leukemia patients.
Journal: Haematologica
Published: October 15, 2025
Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia.
Journal: Leukemia
Published: August 26, 2025
Outcome of Adult Lymphoblastic Lymphoma Patients Treated in the Real Life According to the Gimema LAL1913 Protocol: A Campus ALL Multicenter Study.
Journal: Hematological oncology
Published: June 23, 2025
Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group.
Journal: Annals of hematology
Published: May 30, 2025
Identifying people with acute lymphoblastic leukemia who are most suitable for treatment with inotuzumab ozogamicin: a plain language summary.
Journal: Expert review of hematology
Published: May 21, 2025
Last Updated: 09/26/2026